Breaking News

Amicus, Blackstone Enter $430M Strategic Financing Collaboration

Blackstone Life Sciences and Blackstone Credit to provide a $400 million term loan and a $30 million strategic investment in Amicus.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amicus Therapeutics, Inc., a global biotechnology company focused on developing medicines for rare diseases, has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone. Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus.   Bradley Campbell, President and Chief Executive Officer of Amicus The...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters